Sugi Predict

Sugi Predict / Compounds / SCHEMBL9200583

SCHEMBL9200583

SCHEMBL9200583

Nc1nc2c(ncn2[C@@H]2O[C@H](CO)C[C@@H]2O)c(=O)[nH]1

nearest known ligand 0.53

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ ADORA3 P0DMS8 1/20 0.53
▸ STING1 Q86WV6 3/20 0.52
▸ PDE3B Q13370 1/20 0.52
▸ PDE3A Q14432 1/20 0.52
▸ HPGD P15428 2/20 0.51
▸ HINT1 P49773 2/20 0.51
▸ NT5E P21589 1/20 0.51
▸ POLB P06746 1/20 0.50
▸ TGM2 P21980 1/20 0.49
▸ PNP P00491 1/20 0.49
▸ TLR7 Q9NYK1 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16695880 1.00 ADORA3 (0.53) ADORA3STING1PDE3BPDE3AHPGD
SCHEMBL11929887 1.00 ADORA3 (0.53) ADORA3STING1PDE3BPDE3AHPGD
SCHEMBL98906 1.00 ADORA3 (0.53) ADORA3STING1PDE3BPDE3AHPGD
SCHEMBL4323450 1.00 ADORA3 (0.53) ADORA3STING1PDE3BPDE3AHPGD
SCHEMBL13833321 1.00 ADORA3 (0.53) ADORA3STING1PDE3BPDE3AHPGD
SCHEMBL18759056 1.00 ADORA3 (0.53) ADORA3STING1PDE3BPDE3AHPGD
SCHEMBL98907 1.00 ADORA3 (0.53) ADORA3STING1PDE3BPDE3AHPGD
SCHEMBL12031117 1.00 ADORA3 (0.53) ADORA3STING1PDE3BPDE3AHPGD
Phosphoric Acid SCHEMBL16213328 0.96 NT5E (0.54) ADORA3STING1PDE3BPDE3AHPGD
SCHEMBL23633225 0.92 ADORA3 (0.51) ADORA3STING1PDE3BPDE3AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11857560-B2 Pharmaceutical compositions comprising substituted nucleotides and nucleosides for treating viral infections EMORY UNIVERSITY (US) 2024-01-02 — — US disclosed
US-11166973-B2 Substituted nucleotides and nucleosides for treating viral infections EMORY UNIVERSITY (US) 2021-11-09 — — US disclosed
US-20190298750-A1 Nucleotide and Nucleoside Therapeutic Compositions and Uses Related Thereto DEFENSE THREAT REDUCTION AGENCY, US DOD 2019-10-03 — — US disclosed
US-20160220595-A1 NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO DEFENSE THREAT REDUCTION AGENCY, US DOD 2016-08-04 — — US disclosed
US-9139604-B2 Antiviral phosphonate analogs GILEAD SCIENCES, INC. (US) 2015-09-22 — — US disclosed
US-9139604-B2 Antiviral phosphonate analogs GILEAD SCIENCES, INC. (US) 2015-09-22 — — US disclosed
US-20150025039-A1 ANTIVIRAL PHOSPHONATE ANALOGS GILEAD SCIENCES, INC. 2015-01-22 — — US disclosed
US-20150025039-A1 ANTIVIRAL PHOSPHONATE ANALOGS GILEAD SCIENCES, INC. 2015-01-22 — — US disclosed
US-8871785-B2 Antiviral phosphonate analogs GILEAD SCIENCES, INC. (US) 2014-10-28 — — US disclosed
US-20110288053-A1 ANTIVIRAL PHOSPHONATE ANALOGS GILEAD SCIENCES, INC. (US) 2011-11-24 — — US disclosed
US-8022083-B2 Antiviral phosphonate analogs GILEAD SCIENCES, INC. (US) 2011-09-20 — — US disclosed
US-20110071101-A1 Nucleoside Phosphonate Analogs BOOJAMRA CONSTANTINE G 2011-03-24 — — US disclosed
US-20090275535-A1 ANTIVIRAL PHOSPHONATE ANALOGS GILEAD SCIENCES, INC. 2009-11-05 — — US disclosed
US-20090275535-A1 ANTIVIRAL PHOSPHONATE ANALOGS GILEAD SCIENCES, INC. 2009-11-05 — — US disclosed
US-7429565-B2 Antiviral phosphonate analogs GILEAD SCIENCES, INC. (US) 2008-09-30 — — US disclosed
US-7429565-B2 Antiviral phosphonate analogs GILEAD SCIENCES, INC. (US) 2008-09-30 — — US disclosed
US-5476931-A Reacting with a base in a mixed solvent containing alcohol RIKAGAKU KENKYUSHO (JP) 1995-12-19 — — US disclosed
EP-0311694-B1 NUCLEOSIDE DERIVATIVES AND PROCESS FOR THEIR PREPARATION RIKAGAKU KENKYUSHO (JP) 1995-12-13 — — EP disclosed
US-5144018-A Antiviral Agents RIKAGAKU KENKYUSHO (JP) 1992-09-01 — — US disclosed
EP-0311694-A1 NUCLEOSIDE DERIVATIVES AND PROCESS FOR THEIR PREPARATION RIKAGAKU KENKYUSHO (JP) 1989-04-19 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160220595-A1 NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO PNP, NTPCR, TYMP ADORA3 114/4885STING1 328/4885PDE3B 1744/4885
US-20150025039-A1 ANTIVIRAL PHOSPHONATE ANALOGS TYMP, ITPA, PNP ADORA3 936/4885STING1 32/4885PDE3B 2222/4885
US-20110071101-A1 Nucleoside Phosphonate Analogs TYMP, PNP, NUDT1 ADORA3 167/4885STING1 843/4885PDE3B 1334/4885
US-20110288053-A1 ANTIVIRAL PHOSPHONATE ANALOGS TYMP, ITPA, PNP ADORA3 936/4885STING1 32/4885PDE3B 2222/4885
US-20090275535-A1 ANTIVIRAL PHOSPHONATE ANALOGS TYMP, ITPA, PNP ADORA3 936/4885STING1 32/4885PDE3B 2222/4885
US-11166973-B2 Substituted nucleotides and nucleosides for treating viral infections PNP, TYMP, HPRT1 ADORA3 82/4885STING1 136/4885PDE3B 1029/4885
US-11857560-B2 Pharmaceutical compositions comprising substituted nucleotides and nucleosides for treating viral infections SLC28A1, PNP, SLC28A2 ADORA3 26/4885STING1 128/4885PDE3B 243/4885
US-20190298750-A1 Nucleotide and Nucleoside Therapeutic Compositions and Uses Related Thereto PNP, NTPCR, TYMP ADORA3 114/4885STING1 328/4885PDE3B 1744/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.